Title page

Title

Molecular characterization of liver steatosis through circulating proteins, metabolites and lipids

Short Title

Blood-based profiling of liver steatosis

Authors

Marilyn De Graeve[1], Essi Hantikainen[1], Philippine Louail[1], Vinicius Verri Hernandes[1,2], Cristian Pattaro[1], Francisco S. Domingues[1], Peter P. Pramstaller[1], Herbert Tilg[3], Markus Ralser[4,5,6], Christoph Grander[3,*], Johannes Rainer[1,*]

Affiliations

[1]Institute for Biomedicine, Eurac Research, 39100 Bolzano, Italy

[2]Faculty of Chemistry, Department of Food Chemistry and Toxicology, University of Vienna, Währinger Straße 38, 1090 Vienna, Austria

[3]Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, 6020 Innsbruck, Austria

[4]Institute of Biochemistry, Charité Universitätsmedizin Berlin, 10117 Berlin, Germany

[5]Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany

[6]The Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK

* Contributed equally

Corresponding author

Christoph.Grander@i-med.ac.at

ORCIDs

Marilyn De Graeve: 0000-0001-6916-401X

Essi M. Hantikainen: 0000-0002-4155-2894

Philippine Louail: 0009-0007-5429-6846

Vinicius Verri Hernandes: 0000-0002-3057-6460

Cristian Pattaro: 0000-0002-4119-0109

Francisco S. Domingues: 0000-0003-4567-4562

Peter P. Pramstaller: 0000-0002-9831-8302

Herbert Tilg: 0000-0002-4235-2579

Markus Ralser: 0000-0001-9535-7413

Christoph Grander: 0000-0003-2971-6224

Johannes Rainer: 0000-0002-6977-7147

Highlights

- Multi-omics profiling reveals biomarkers associated with hepatic steatosis severity
- Substantial overlap between steatosis biomarkers and metabolic health indicators
- Steatosis-associated profiles reflect broad metabolic dysfunction
- Plant-based diet is associated with lower steatosis grade
- Dietary habits did not affect the identified steatosis blood biomarkers

Abstract

Background:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most prevalent liver disorders in Western countries. While steatosis is prevalent, molecular mechanisms associated with steatosis grades and how nutrition modulates related metabolic disturbances remain poorly understood.

Methods:
We analyzed data from 327 participants of the CHRIS NAFLD study with Type 2 diabetes (T2D) and matched controls, integrating 148 plasma proteins with 175 serum metabolites and lipids to identify circulating biomarkers associated with hepatic steatosis severity. Associations between dietary intake and steatosis were investigated, and a potential influence of diet on the identified biomarkers was evaluated through a sensitivity analysis. Participants were stratified by steatosis grade based on ultrasound-derived measurements.

Results:
Steatosis grade was strongly positively correlated with BMI and T2D. Several proteins (e.g., GC, AFM, AZGP1, SERPINC1, VTN, LRG1) and metabolites (e.g., glutamate, tyrosine, valine, lysoPCs) were associated with the highest steatosis grade, mainly reflecting a broader metabolically unhealthy phenotype. Adherence to a plant-based diet was associated with lower steatosis grades independent of circulating proteins, metabolites, and lipids.

Conclusion:
Results suggest that circulating metabolic signatures of steatosis reflect broader metabolic dysregulation and are independent of dietary intake. These data support the use of blood-based multi-omics profiling to distinguish between metabolically healthy and unhealthy individuals, and may thus improve MASLD risk stratification.

Graphical abstract



Keywords

Hepatic steatosis

Proteomics

Metabolomics and Lipidomics

Mass spectrometry

Blood biomarkers

CHRIS study

Abbreviations

- A1BG – Alpha-1B-glycoprotein
- AA – Amino acid
- AFM – Afamin
- ALT – Alanine aminotransferase
- APO – Apolipoprotein
- AST – Aspartate aminotransferase
- AZGP1 – Zinc-alpha-2-glycoprotein

- BMI – Body mass index
- C – Complement component
- C0 – L-Carnitine
- C3 – Propionylcarnitine
- C3:1 – Propenoylcarnitine
- C4 – Butyrylcarnitine
- C5 – Valerylcarnitine
- C12-DC – Dodecanedioylcarnitine
- CAP – Controlled attenuation parameter
- CF – Complement factor
- CFH – Complement factor H
- CFI – Complement factor I
- CHRIS – Cooperative Health Research in South Tyrol
- CLEC3B – Plasminogen-binding tetranectin
- CP – Ceruloplasmin
- CRP – C-reactive protein
- CV_{QC} – Coefficient of variance of quality control samples
- CVD – Cardiovascular diseases
- FDR – False discovery rate
- FIB4 – Fibrosis-4 score
- FFQ – Food frequency questionnaire
- GA2LEN – Global Allergy and Asthma European Network
- GC – Vitamin D-binding protein
- Gln – Glutamine
- Glu – Glutamate
- GSN – Gelsolin
- HbA1c – Hemoglobin A1C
- HDL – High-density lipoprotein
- HPR – Haptoglobin-related protein
- HCC – Hepatocellular carcinoma
- IGHV1-3 – Immunoglobulin heavy variable 1-3
- IHITs – Inter-alpha-trypsin inhibitor heavy chain
- ITIH3/ITIH4 – Inter-alpha-trypsin inhibitor heavy chain 3/4
- LDL – Low-density lipoprotein
- LRG1 – Leucine-rich alpha-2-glycoprotein
- MASLD – Metabolic dysfunction–associated steatotic liver disease
- MASH – Metabolic dysfunction–associated steatohepatitis
- MetALD – Metabolic and alcohol-associated liver disease
- MetS – Metabolic syndrome
- MRI-PDFF – Magnetic resonance imaging–proton density fat fraction
- MS – Mass spectrometry
- MSI – Metabolomics Standards Initiative
- NAFLD – Nonalcoholic fatty liver disease
- PC – Phosphocholine

- PDI – Plant-based Diet Index
- QC – Quality control
- Rho – Spearman correlation coefficient
- SDMA – Symmetric dimethylarginine
- SERPIN – Family of serine proteinase inhibitor
- SHBG – Sex hormone-binding globulin
- SLD – Steatotic liver disease
- SM – Sphingomyelin
- T2D – Type 2 diabetes mellitus
- Trp – Tryptophan
- Tyr – Tyrosine
- Val – Valine
- VTN – Vitronectin

Introduction

Hepatic steatosis, characterized by the accumulation of triglycerides in hepatocytes, is a key feature in diagnosing metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD has become a significant public health concern due to its rising prevalence and its potential to progress into more severe liver conditions, including metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis and hepatocellular carcinoma (HCC). Steatosis is considered a hepatic manifestation of metabolic syndrome (MetS), and is strongly associated with obesity, type 2 diabetes (T2D) as well as chronic cardiovascular diseases (CVD).[1–4]

Dietary factors play an essential role in the development as well as management of MASLD. Previous literature has shown variations in macronutrient intake by MASLD status.[5] Steatosis is closely and bidirectionally linked to hepatic and peripheral insulin resistance, particularly in obese individuals.[6] Insulin resistance leads to increased lipolysis in adipose tissue, as well as altered de-novo lipogenesis in hepatocytes, resulting in triglyceride accumulation.[7] Therefore, plant-based diets are gaining attention as a sustainable and health-conscious alternative for managing liver disease.[8]

Hepatic steatosis is commonly assessed using indirect or semi-quantitative methods, such as liver enzyme levels, imaging surrogates like computed tomography (CT) attenuation, or scoring systems based on clinical and metabolic parameters. However, these approaches lack the sensitivity and specificity to accurately quantify liver fat content, particularly in early or moderate stages of steatosis.[9-12] More recent studies have adopted non-invasive methods like controlled attenuation parameter (CAP), obtained during a liver stiffness measurement (FibroScan®), to provide a feasible, more precise, quantitative assessments of hepatic fat.[13-15]

Advances in multi-omics technologies, such as proteomics, metabolomics, and lipidomics, offer new avenues to study the molecular mechanisms underlying steatosis and its progression. The application of high-throughput omics technologies to study steatosis not only enhances our understanding of its molecular drivers but also paves the way for targeted prevention and treatment strategies to halt or reverse the

progression of liver disease.

To further explore the link between steatosis and its proteomic and metabolic influences, we use cross-sectional data from the CHRIS NAFLD study cohort (n=327 participants)[15], with participants recruited from the Cooperative Health Research in South Tyrol (CHRIS) study[16,17], that includes individuals with varying liver steatosis grades. By combining plasma proteomics (148 proteins) with serum metabolite and lipid profiling (175 metabolites), we investigate how such circulating biomarkers could help classify liver steatosis severity and assess the role of diet.

Material and Methods

Study cohort

The Cooperative Health Research in South Tyrol (CHRIS) study is a population-based cohort of 13,393 adults aged 18 and over, recruited in the alpine Val Venosta/Vinschgau district in South Tyrol (Italy).[16,17] For the CHRIS NAFLD study 356 participants of the CHRIS study with and without a diagnosis of T2D were recalled and additional phenotyping and sample collection performed.[15]

Classification of steatosis

To evaluate the presence of hepatic steatosis and hepatic fibrosis, different non-invasive measurement tools were used. For liver steatosis assessment, participants underwent abdominal transient elastography (Fibroscan®, Echosens, France) after overnight fasting.[15] The presence and severity of steatosis was evaluated as documented by Ballestri et al.[18] Steatosis was quantified using CAP[19], and individuals were classified into four groups, corresponding to varying steatosis grades. Control participants, having no abnormally increased liver fatty change, were defined as having a CAP score from ≥0 to <238 dB/m. Grade 1, 2, and 3 steatosis was defined as a CAP of ≥238 to ≤260 dB/m, >260 to ≤290 dB/m, and >290 to ≤400 dB/m, respectively.[20]

Related liver parameters (hepatic fibrosis, MASH, visual fat, MALSD, and MetS) are discussed in the Supplementary Information (SI information 1).

Proteomics and metabolomics, including lipids, data

Generation of the plasma proteomics and serum metabolomics data for the present study was performed along with the data for the CHRIS study and is described in detail elsewhere.[21,22] The data sets consist of 148 plasma proteins (Supplementary Table S1) and 175 metabolites and lipids (Biocrates AbsoluteIDQ® p180 kit. Supplementary Table S2).

Additional untargeted metabolomics analysis was performed, described under SI information 2.

Dietary intake

Dietary intake was assessed using the self-administered, semi-quantitative Global Allergy and Asthma European Network (GA2LEN) food frequency questionnaire (FFQ)[23], which has been described in detail elsewhere.[24] The FFQ records the consumption of 229 foods and beverages, that were categorized into 32 sections. Participants were asked to report their average consumption frequencies for the past 12 months for each item, considering standard portion sizes. Consumption frequency of specific food items was transformed into grams per day and converted into specific macronutrient estimates using the latest edition of the McCance & Widdowson's Food Composition Tables.[25] Total energy intake (TEI, in kcal) was estimated as energy coming from proteins (4 kcal/g), fat (9 kcal/g), carbohydrates expressed as monosaccharides (3.75 kcal/g) and alcohol (7 kcal/g).[26]

Daily protein, carbohydrate and fat intake was estimated expressed as percentage of TEI per day (protein %energy = (protein in g × 4 kcal/g)/TEI in kcal) × 100; carbohydrates %energy = (carbohydrates in g × 3.75 kcal/g)/TEI in kcal) × 100; fat %energy = (fat in g × 9 kcal/g)/TEI in kcal) × 100). We additionally distinguished between saturated, polyunsaturated, monounsaturated and trans fatty acids.

For the Plant-based Diet Index (PDI) score, the FFQ items were categorized into eighteen food groups as outlined by Satja et al.[27] The consumption of the index was expressed in servings/day. After categorizing intake into quintiles, a positive score was assigned to the "healthy" and "less-healthy"/"unhealthy" plant foods, and a reverse score to the animal-based foods. For the positively scored items participants with an intake above the highest quintile received a score of 5 and those below the lowest quintile intake received a score of 1. Reverse values were assigned for the reversely scored items. For each participant, the individual scores of the 18 food groups were then summed up to create the final score.

Statistical data analysis

The data analysis workflows are available in the GitHub repository https://github.com/EuracBiomedicalResearch/nafld_proteo_metabolomics. Data analysis was conducted in R v4.5.2. Samples from individuals with missing values in any of the covariates were excluded. Steatosis measurements with a Fibroscan liver stiffness interquartile range score above 30 were removed. The final data sets used in all analyses were restricted to samples without missing values in any of the covariates (steatosis, age, sex) and available metabolomics, proteomics and FFQ data; and consisted of data from n=327 participants. Protein and metabolite abundances were log2 transformed and had log-normal distributions.[21,22] Only the metabolomics data had missing values (1.24%), no imputation was performed.

Correlation analysis with steatosis and fibrosis

Correlation tests (Spearman's rank) were performed to evaluate initial associations between steatosis and other potentially relevant measurements available for CHRIS NAFLD study participants (listed in Table 1). The resulting p-values were adjusted for multiple hypothesis testing using the method from Benjamini and Hochberg and associations with an adjusted p-value<0.05 were considered significant.

Multiple linear regression analysis

Multiple linear regression analyses were performed for the proteomics data (148 proteins), targeted metabolomics data (175 metabolites and lipids), FFQ derived macronutrients (7 items), and the PDI score. A separate model was fitted for each of these analytes explaining the response variable (e.g. abundance of a protein) by the covariates steatosis grade (categorical), age and sex (binary). For dietary intake, the estimated daily total energy intake (kcal) was additionally included as an explanatory variable in the models. Significant response variables were defined based on the coefficient for steatosis grade 3, which represents the difference between individuals with the highest steatosis grade (n = 81) and the base level (n = 140). The p-values for this coefficient were adjusted for multiple hypothesis testing using the Benjamini-Hochberg method for a strong control of the false discovery rate (FDR). Associations with an adjusted p-value<0.05 were considered statistically significant. For increased confidence, we required for protein, metabolite and lipid associations, in addition to the statistical significance, that also the observed difference in concentrations was more than 50 times higher than the coefficient of variation (CV) of a particular analyte. This CV represents the technical variance of a measurement estimated on the available study-internal quality control samples.

Sensitivity analyses

To evaluate potential confounding of the results by T2D the coefficients for steatosis from the models were compared to those from fitted models that included in addition T2D as an explanatory (categorical) variable.

The influence and potential confounding of the PDI score on the steatosis results was evaluated by comparing coefficients for steatosis between the linear models with and without PDI score as additional explanatory variable.

Pathway analysis

For pathway analysis, UniProt and HMDB IDs for significant proteins and metabolites were submitted to the RAMP-DB (https://rampdb.nih.gov/pathway-enrichment, v3.0.7) online tool.[28] This resource integrates multiple pathway databases, including KEGG, Reactome, and WikiPathways, to perform robust enrichment analyses. Results were exported and served as the basis for downstream clustering and curation.

The enriched pathways for proteins and metabolites were manually reviewed and grouped into biologically meaningful pathway clusters. Particular attention was given to recurring themes across pathways, allowing for aggregation into higher-level biological processes (e.g., amino acid metabolism, lipid metabolism, coagulation cascade).

Results

Characterization of steatosis in the CHRIS NAFLD study cohort

Hepatic steatosis was quantified in 327 participants. Of them, 187 presented grade 1-3 steatosis (57.2%)

while 140 showed no signs of steatosis (42.8%). Characteristics are provided in Table 1.

Table 1. Demographics and relevant clinical parameters of the CHRIS NALFD study cohort (n=327). Numeric values are shown as mean ± standard deviation (SD). Binary variables are shown in percentages. BMI, Body Mass Index; HbA1c, hemoglobin A1C; T2D, Type 2 Diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Gamma-GT, gamma-glutamyl transferase; CRP, C-reactive protein; IQR, interquartile range; FIB4, Fibrosis-4 index; MASLD, Metabolic Dysfunction Associated Steatotic Liver Disease; MetALD, MASLD and increased alcohol intake; SLD, steatotic liver disease; MetS, metabolic syndrome.

Relevant Metadata	**Unit**	**Female – No hepatic steatosis**	**Female – Hepatic steatosis grade 1**	**Female – Hepatic steatosis grade 2**	**Female – Hepatic steatosis grade 3**	**Male – No hepatic steatosis**	**Male – Hepatic steatosis grade 1**	**Male – Hepatic steatosis grade 2**	**Male – Hepatic steatosis grade 3**
General specification									
Sex	% male	0	0	0	0	40.9	14.6	15.9	28.7
	% female	45.3	17.4	16.9	20.3	0	0	0	0
Age	years	66.06 ± 12.14	70.57 ± 8.61	69.34 ± 9.48	66.94 ± 8.91	68.40 ± 11.68	69.75 ± 10.13	69.27 ± 8.50	64.87 ± 9.64
Body composition									
BMI	kg/m2	25.98 ± 4.48	27.11 ± 3.83	30.28 ± 5.92	32.04 ± 5.35	26.11 ± 3.68	26.93 ± 2.61	28.98 ± 4.32	29.84 ± 4.38
Weight	kg	65.39 ± 12.26	68.20 ± 10.44	74.10 ± 13.81	80.47 ± 14.61	77.43 ± 12.21	77.83 ± 10.63	84.72 ± 13.85	89.96 ± 14.89
Visceral fat thickness	mm	8.65 ± 2.79	10.10 ± 3.03	11.27 ± 3.39	12.20 ± 2.49	11.33 ± 4.79	12.52 ± 3.42	14.22 ± 3.79	15.44 ± 5.01
Body fat, i.e. subcutaneous fat thickness	mm	37.34 ± 7.42	38.91 ± 6.14	42.81 ± 7.45	45.32 ± 5.10	22.69 ± 6.22	24.71 ± 4.85	26.48 ± 4.18	28.35 ± 6.03
Ratio visceral to subcutaneous fat thickness	-	0.23 ± 0.04	0.26 ± 0.06	0.26 ± 0.04	0.27 ± 0.04	0.48 ± 0.11	0.51 ± 0.09	0.53 ± 0.10	0.54 ± 0.09
Waist circumference	cm	84.29 ± 11.63	88.34 ± 11.13	94.83 ± 13.26	100.13 ± 10.97	93.32 ± 11.48	95.09 ± 7.34	101.47 ± 8.25	103.69 ± 11.20
Carbohydrate, energy metabolism									
Glucose	mg/dl	96.67 ± 18.18	104.47 ± 49.39	106.79 ± 20.58	123.43 ± 26.20	106.03 ± 25.16	114.25 ± 32.88	124.77 ± 42.74	114.30 ± 27.32
HbA1c	mmol/mol	5.69 ± 0.73	5.78 ± 1.02	5.88 ± 0.95	6.37 ± 0.84	5.71 ± 0.66	5.97 ± 0.85	6.32 ± 1.61	5.99 ± 0.95
T2D	%	14.2	4.7	9.4	20.8	16	8.5	10.4	16
Diabetes medication' usage	%	17.3	6.2	8.6	21	16	6.2	11.1	13.6
Alcohol intake									
Alcohol abstinence, self-reported	%	23.3	9.1	8.5	10.6	20.3	6.4	7.9	13.9
Daily total alcohol	g	3.15 ± 5.09	3.97 ± 4.98	5.01 ± 8.51	4.51 ± 8.50	11.87 ± 10.01	13.86 ± 11.42	14.56 ± 11.11	13.61 ± 12.16

Blood pressure									
Systolic blood pressure	mmHg	136.69 ± 24.89	143.07 ± 17.00	133.89 ± 19.45	134.50 ± 17.08	142.93 ± 18.41	139.92 ± 11.96	141.07 ± 12.68	143.31 ± 16.59
Diastolic blood pressure	mmHg	81.24 ± 9.22	85.28 ± 9.18	82.06 ± 8.92	84.65 ± 8.97	83.79 ± 9.43	85.69 ± 7.60	82.92 ± 8.28	87.85 ± 8.91
Blood pressure lowering therapy' usage	%	18.8	7.8	10.4	11.7	20.1	7.1	8.4	15.6
Lipid metabolism									
Triglycerides	mg/dl	92.28 ± 28.36	112.77 ± 45.66	120.34 ± 51.78	135.34 ± 49.91	103.67 ± 50.21	102.54 ± 39.40	121.77 ± 80.66	133.45 ± 56.87
Lipid modifying agents' usage	%	17.5	8.7	12.6	14.6	19.4	6.8	7.8	12.6
HDL	mg/dl	63.47 ± 11.00	60.27 ± 11.37	55.69 ± 13.49	54.71 ± 12.64	55.84 ± 13.72	52.46 ± 12.12	50.62 ± 8.92	48.38 ± 11.17
LDL	mg/dl	134.51 ± 38.19	136.40 ± 33.27	127.14 ± 45.22	131.23 ± 41.61	128.52 ± 35.73	145.46 ± 57.28	118.12 ± 40.57	131.53 ± 43.00
Liver health									
Markers									
AST	U/L	19.46 ± 5.25	19.70 ± 3.96	18.74 ± 4.65	22.63 ± 8.61	20.47 ± 5.38	21.29 ± 6.15	22.58 ± 7.23	22.13 ± 6.26
ALT	U/L	17.28 ± 10.39	16.63 ± 4.44	18.59 ± 9.66	25.11 ± 13.62	20.69 ± 13.53	22.92 ± 8.52	25.54 ± 10.73	28.53 ± 15.24
Gamma-GT	U/I	23.08 ± 31.97	22.50 ± 14.25	27.28 ± 19.47	40.34 ± 69.77	29.66 ± 15.44	48.46 ± 79.75	45.62 ± 26.77	45.43 ± 34.19
ALP	U/I	73.45 ± 23.24	77.53 ± 15.81	78.21 ± 17.92	79.00 ± 21.99	68.40 ± 17.54	73.88 ± 16.11	70.27 ± 24.26	66.64 ± 17.60
Total bilirubin	mg/dl	0.81 ± 0.35	0.80 ± 0.38	0.70 ± 0.32	0.84 ± 0.34	1.04 ± 0.55	0.97 ± 0.56	1.01 ± 0.53	1.00 ± 0.43
Direct bilirubin	mg/dl	0.29 ± 0.10	0.28 ± 0.11	0.25 ± 0.09	0.29 ± 0.10	0.36 ± 0.19	0.34 ± 0.15	0.35 ± 0.13	0.34 ± 0.12
CRP	mg/dl	0.25 ± 0.30	0.17 ± 0.12	0.43 ± 0.50	0.34 ± 0.49	0.23 ± 0.25	0.18 ± 0.10	0.33 ± 0.37	0.30 ± 0.38
Steatosis									
No steatosis	%	53.8	0	0	0	46.2	0	0	0
Steatosis grade 1	%	0	55.6	0	0	0	44.4	0	0
Steatosis grade 2	%	0	0	52.7	0	0	0	47.3	0
Steatosis grade 3	%	0	0	0	42.7	0	0	0	57.3
MASLD	%	7.7	10.1	13.7	17.9	10.7	6.5	10.1	23.2
Fibrosis									
Liver stiffness	dB/m	3.84 ± 1.35	3.97 ± 1.23	6.14 ± 6.34	5.75 ± 2.93	4.48 ± 1.81	5.00 ± 0.89	5.06 ± 1.70	5.48 ± 2.51
FIB4	-	1.37 ± 0.58	1.47 ± 0.46	1.24 ± 0.58	1.30 ± 0.59	1.55 ± 0.71	1.51 ± 0.59	1.47 ± 0.50	1.42 ± 0.51

To further characterize hepatic steatosis, Spearman analyses were performed to infer initial correlations between steatosis and potential covariates, which included clinical, anthropometric and demographic parameters (Table 2). Anthropometric parameters, such as BMI, weight or visceral fat were all positively

correlated with steatosis grade (Table 2, Figure 1), while no such relationship was found for other variables, such as age (Table 1).

Table 2. Relevant clinical information significantly associated with steatosis. Only variables with an absolute Rho>0.2, and FDR adjusted p-value<0.05 were retained. Rho, Spearmen correlation coefficient. BMI, Body Mass Index; HbA1c, hemoglobin A1C; T2D, Type 2 Diabetes mellitus; HDL, high-density lipoprotein; MASLD, Metabolic Dysfunction Associated Steatotic Liver Disease; MetS, metabolic syndrome.

Variable	**Rho**	**Adjusted p-value**
Visual fat	0.58	5.71E-25
MASLD	0.55	1.79E-21
Waist circumference	0.46	5.19E-15
BMI	0.46	5.98E-14
Visceral fat	0.43	4.55E-12
Glucose	0.36	2.21E-09
Liver stiffness	0.35	4.12E-08
MetS	0.33	3.25E-08
HDL	-0.29	2.18E-06
Triglycerides	0.28	3.52E-06
T2D	0.27	1.17E-05
HbA1c	0.27	1.43E-05
Body fat, i.e. subcutaneous fat thickness	0.24	1.88E-04
Diabetes medication' usage	0.21	6.41E-04



Figure 1. Distribution of steatosis classification by sex and BMI among study participants.

Steatosis, measured using the categorized objective liver fat metric, was strong, and positively correlated with MASLD (Rho=0.55, FDR p-value=1.79E-21; Table 2). Other notable significantly correlated variables (|Rho|>0.20, FDR p-value<0.05) are presented in Table 2. The highest positive correlation was with visual fat, another, but more subjective, way to measure steatosis (SI information 1). Similarly, the thickness of visceral fat, subcutaneous fat, and the waist circumference were also all positively correlated with steatosis. To a lesser extent, carbohydrate metabolism and T2D were positively correlated as well. As liver stiffness was positively correlated with steatosis, circulating proteins, metabolites and lipids associated with liver fibrosis or MASH were additionally investigated (SI information 1). Triglycerides and glucose were also positively correlated, while the concentration of HDL was negatively correlated with steatosis.

Circulating proteins, metabolites and lipids significantly associated with liver steatosis

Using multiple linear regression analyses we next evaluated associations between circulating protein or metabolite abundances and (categorical) steatosis grade, adjusting in addition for the participants' age and sex. For the proteomics data, the number of significant associations increased with the steatosis grade (see Figure 2A, Supplementary Figure S1). From the tested 148 circulating proteins, 2, 5 and 24 were found to have significantly different abundances between steatosis grade 1, 2, and 3 and the control group, with also the magnitude of this difference increasing with steatosis grade (Table S3). For the circulating metabolites and lipids, no, 58 and 48 molecules were found significantly associated with steatosis grade 1, 2 and 3, respectively (Table S4). In contrast to the proteomics data, the set of significant metabolites and lipids was

only partially overlapping for steatosis grades 2 and 3. This less-linear trend has already been noted before.[29] Some metabolites, however, in particular glutamate and alpha-AAA showed strong and increasing concentrations with the steatosis grade. These results were independent of T2D as shown in a sensitivity analysis (Figure S2).



Figure 2. Circulating proteins, metabolites and lipids significantly associated with different grades of liver steatosis. Number of significant circulating proteins, metabolites, and lipids between the control and grade 1 steatosis, the control and grade 2 steatosis, and the control and grade 3 steatosis comparisons, respectively (A). Hierarchical clustered heatmap depicting trends among the different steatosis grades comparisons of proteins (B) and metabolites and lipids (C). Shown are coefficients from the regression models in steatosis

grade 1, 2 and 3 against control individuals, respectively. Only analytes with at least one significant association are shown. Asterisks depict significant coefficients. Positive values indicate higher abundance in steatosis grades, negative values higher abundance in control individuals.

Grade 3 steatosis associated plasma proteome

As steatosis grades are associated with increased risk for MASH and development of fibrosis[30], we focused our analysis on the metabolic characterization of grade 3 steatosis. When comparing participants with no obvious steatosis versus participants with high grade steatosis, 24 proteins (Table S3) and 48 small molecules (metabolites and lipids, Table S4) were significantly associated (Figure S1). Steatosis-related circulating proteins represent Inter-alpha-trypsin inhibitor heavy chain proteins (ITIHs), apolipoproteins (APOs), serine proteinase inhibitors (SERPINs), complement components and - factors, and individual proteins. Abundance of ITIH3 and ITIH4 was significantly lower in grade 3 steatosis compared to control. Regarding apolipoproteins, APOD and APOM were significantly lower in high-grade steatosis participants. The significant SERPINs SERPINA3, SERPINA6 and SERPINC1 were less abundant, while SERPIND1 was more abundant in grade 3 steatosis. The complement components C3 and C9 behaved oppositely, with C3 being higher, and C9 lower abundant in grade 3 steatosis. The complement factor H (CFH), Complement factor I (CFI) and immunoglobulin heavy variable 1-3 (IGHV1-3) were all significantly higher in steatosis. Afamin (AFM), involved in vitamin E transport, and Vitronectin (VTN), involved in cell adhesion, are both more abundant in grade 3 steatosis. Vitamin D-binding protein (GC), leucine-rich alpha-2-glycoprotein (LRG1), sex hormone-binding globulin (SHBG), zinc-alpha-2-glycoprotein (AZGP1), haptoglobin-related protein (HPR), gelsolin (GSN), alpha-1B-glycoprotein (A1BG) and the liver-secreted ceruloplasmin (CP) were all lower in grade 3 steatosis.

Grade 3 steatosis associated blood serum metabolome

Grade 3 steatosis is related to several circulating polar metabolites, representing 10 amino acids (AAs), a hexose sugar, two biogenic amines and 6 (acyl)carnitines. Of the AAs, only glycine and glutamine (Gly, Gln) were less abundant with steatosis. The other common AAs Ala, Glu, Ile, Leu, Phe, Val, Tyr and Trp were up. Also, two biogenic amines, α-Aminoadipic acid (alpha-AAA) and symmetric dimethylarginine (SDMA) were found to be significantly associated with grade 3 steatosis. An unidentified hexose (H1) is also identified in relation to grade 3 steatosis, being more abundant compared to control individuals. The short-chain (acyl)carnitines: L-Carnitine (C0), Propionylcarnitine (C3), Propenoylcarnitine (C3:1), Butyrylcarnitine (C4), and Valerylcarnitine (C5) were all significantly and positively associated with grade 3 steatosis. The medium-chain dioylcarnitine Dodecanedioylcarnitine (C12-DC) was negatively associated with grade 3 steatosis.

Grade 3 steatosis associated blood serum lipidome

For the apolar metabolites, the lipid classes with significant differences between grade 3 steatosis and controls comprise lipid species from 25 glycerophospholipids and 4 sphingolipids. All glycerophospholipids were either lyso- (lysoPCs, 4#) or phosphocholines (PCs, 21#) and were less

abundant with steatosis, except for the phosphocholine PC aa C32:1, which was higher. The significantly lower abundancy of PC represented species with variable acyl chain length, both saturated and (poly)unsaturated fatty acid chains; and both fatty acyl / fatty acyl (denoted 'aa') and fatty acyl / fatty alcohol (denoted 'ae') bound acyls attached. Therefore, conclusions on why PC aa C32:1 concentration behaved opposite to the other significant PCs between participants with and without grade 3 steatosis are difficult to draw. The sphingolipids, three sphingomyelins (SM C16:0, SM C20:2, SM C24:1) and one hydroxylated sphingomyelin (SM(OH) C22:2) were less abundant in participants with grade 3 steatosis.

Associations between dietary intake and steatosis characterization

We next investigated a possible relationship between dietary habits and steatosis. No strong significant difference in macronutrient intake was observed between grade 3 steatosis participants and controls (Figure S3A). However, a significant negative association between plant-based diet (PDI) and steatosis was found (Figure S3A). Individuals with grade 3 steatosis scored significantly lower on the PDI (Table S5), and the directionality of this food index along steatosis grades followed the expected patterns. To evaluate a potential influence of these dietary habits on the identified steatosis-associated circulating biomarkers, sensitivity analyses were performed employing linear regression analyses with and without the PDI score as covariate in the proteomics and metabolomics datasets, respectively. The results from these models were highly similar, arguing against an influence of dietary intake on the present results (Figure S3B). Therefore, in our cohort, dietary habits did not explain the observed differences in concentrations of circulating proteins, metabolites, and lipids.

Biological pathway alterations in grade 3 steatosis

To investigate the underlying pathways contributing to liver fat accumulation and related metabolic disturbances in steatosis, the molecular, dietary intake and clinical findings were integrated. There was no overlap in biological pathways, investigating biochemical metabolism, signaling and regulation pathways, transportation, between the significant proteins and small molecules (Figure S4).

The full list of individual pathways of the significantly altered proteins, metabolites and lipids are presented in Table S6 but will not be discussed below, as no biologically relevant conclusions can be drawn based on a single up- or downregulated molecule per pathway. In particular, when the same protein or analyte is involved in multiple biological processes.

Altered pathways involving steatosis grade 3 associated circulating proteins

Pathway enrichment analysis for grade 3 associated proteins revealed three clusters, and the bulk of significant pathways were defined as 'not clustered' (Figure S4A). Upon manual curation, 3 enriched pathways were defined to be of interest. These are discussed further in SI information 3. A fourth enriched pathway, the post-translational protein phosphorylation (Reactome R-HSA-381426), containing the phosphorylation of C3, CP, SERPINC1 and SERPIND1, was considered not of interest as these belonged to a broad range of secreted proteins that are phosphorated by the extracellular serine/threonine protein kinase (FAM20C).

Most of the significant differentiating proteins can be summarized under one enriched pathway, the broad umbrella of the complement and coagulation cascades (Figure 3, wiki pathways WP558). Under this super pathway, C3, C9, VTN, CFI and CFH are involved in the complement system, with unbound unassociated C3 playing a central role in the activation of complement system required for both classical and alternative complement activation pathways, while SERPINC1 and SERPIND1 are involved in the coagulation (specifically in the fibrin clot formation).



Figure 3. Altered biochemical pathways steatosis grade 3 associated proteins. Complement and coagulation cascades. Figure based on Wikipathways (WP558; 20250301134720), which is based on KEGG pathway (map04610). Red boxes indicate higher abundance in steatosis grade 3, blue boxes higher abundance in control individuals. Boxplots left, control; right, grade 3 steatosis.

Altered pathways involving steatosis grade 3 associated circulating metabolites and lipids

Pathway enrichment analysis for grade 3 associated metabolites and lipids revealed 15 clusters, excluding

significant pathways which were defined as 'not clustered' (Figure S4B). Upon manual curation, 3 enriched umbrella pathways of the central metabolism were defined to be of interest. The involved metabolites can act both as a cellular building block (e.g. AAs for protein biosynthesis) and as signaling molecules (e.g. Trp, Tyr, Glu) which rendered segregation into separate pathways difficult.

The bulk of significant metabolites fall under the umbrella of extended amino acid metabolism, including the -with multiple AA- enriched synthesis or catabolism pathways (Table S6, Figure S4). In addition, AAs are derived from proteins from the diet, but no significant differences in protein intake (derived from FFQ data) were found. Therefore, the significantly altered AAs and their direction from control to grade 3 steatosis, were summarized under their amino acid biosynthesis pathway (Figure 4). In addition, alpha-AAA, precursor in the biosynthesis of lysine (through the α-aminoadipate pathway) is also represented in Figure 4. To show the link with SDMA, technically a protein with 2 arginine residues, the free amino acid arginine is depicted in Figure 4 with a dotted line.

The other important biochemical pathways are discussed further in SI information 4. Lastly, additional untargeted metabolomic analysis was performed, retrieving a total of 10,882 metabolic features. Upon linear modeling (control vs steatosis grade 3), the Mummichog algorithm was applied on their associated FDR adjusted p-values to retrieve steatosis grade 3 associated biochemical pathways and the involved metabolites. Using this approach, three new putative metabolites (MSI level 4: N-Acetylmethionine, 1-Pyrroline-4-hydroxy-2-carboxylate and L-4-Hydroxyglutamate semialdehyde) were found, which were visually added to the amino acid pathway in SI information 2.



Figure 4. Altered biochemical pathways of differentiating metabolites and lipids between control and grade 3 steatosis: biosynthesis and uptake of amino acids. Figure based on KEGG, enzyme reaction catalyzed in humans in green lines, closely related amino acid in dashed box (Kanehisa Laboratories 01230 10/24/23). Red boxes indicate higher abundance in steatosis grade 3, blue boxes higher abundance in control individuals. Boxplots left, control; right, grade 3 steatosis.

Discussion

In this study, we aimed to investigate circulating protein, metabolite, and lipid profiles associated with hepatic steatosis severity, using samples from a well-characterized, fasting, single-site population cohort. Our analyses identified a set of proteins and metabolites significantly altered in participants with grade 3 steatosis (Table 3). Among the most consistent protein markers were vitamin D-binding protein (GC), afamin (AFM), zinc-alpha-2-glycoprotein (AZGP1), antithrombin-III (SERPINC1), vitronectin (VTN), and

leucine-rich alpha-2-glycoprotein (LRG1). Metabolites such as glutamate, tyrosine, valine, and various PCs and (lyso)PCs also showed significant differential abundance.

Although being defined by different measures, the sets of MASLD and steatosis grade 3 participants are highly overlapping in our cohort. This confirms and expands on an earlier report of circulating multi-protein signatures of hepatic steatosis being strongly associated with liver disease and multi-system metabolic outcomes.[31] Therefore, the proteome and metabolome results are not exclusively related to a progression of steatosis but reflect a more general transition from a metabolically healthy to unhealthy phenotype. Triglycerides and glucose were also positively correlated to steatosis and can be linked to the increased levels of complement component 3 in grade 3 steatosis. Changes in circulating molecules, such as higher triglycerides, most likely originate from secretion from the liver and not from the diet as no associations between daily fat intake or any other fatty acid related macronutrients and steatosis were observed.

Table 3. Circulating proteins, metabolites, and lipids associated with grade 3 steatosis. Variable: significant protein, metabolite or lipid. Direction: abundance in high grade steatosis relative to control individuals. Discussion, summary of the protein, metabolite or lipid function in context of the relevant literature.

Variable	**Direction**	**Discussion**
Proteins		
ITIHs	Lower	Interestingly, ITIH4 was previously described to be an acute-phase protein and novel biomarker for cholestatic liver disease.[32] Furthermore, ITIH4 was proposed as a biomarker for fibrosis in hepatitis C.[33,34] ITIH3 was recently described as an important regulator of hepatic steatosis, as knock-down of ITIH3 in a murine model led to increased hepatic triglyceride accumulation in different models of MASLD.[35]
APOs	Lower	The APOD and APOM proteins were thus far not discussed in steatosis research, but expression of the gene Apo M has been reported to be significantly lower in steatotic liver disease, independently if MASLD is present of not.[36] As the liver is a major organ in fatty acid metabolism, these results are not unexpected.
SERPINs	Depending molecular species	The significant SERPINs have not yet been described in relation to steatosis, except for SERPINE1 (UniProt P05121), which was not measured in this study.[37]
Complement compounds, CFs and immunoglobulins	Depending molecular species	As complement compounds, CFs and immunoglobulins are involved in the inflammatory processes, these differences suggest changes in the immune response pathways during steatosis development. Increased levels of C3 in grade 3 steatosis stimulates triglyceride synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial triglyceride clearance.[38,39]
AFM and VTN	Higher	These findings were consistent with results from murine studies on their protein equivalents (AFM60 and VTN)[40], and were retrieved as functional biomarkers of hepatic steatosis in humans.[41] Therefore, a shared biology between mice and humans in the hepatic steatosis development was suggested.
AZGP1	Lower	AZGP1 is normally responsible for lipid degradation stimulation in adipocytes but is less abundant in steatosis participants, suggesting lipid metabolism dysfunction (i.e. more triglycerides).
HPR	Lower	HPR is the main plasma protein associated with APOL-I-containing high-density lipoprotein (HDL), so a downregulation of this protein suggests lipid metabolism dysfunction as well.

GSN	Lower	GSN is overexpressed in MASH patients and reported to have a protective role in MASH through F-actin regulation and P53 degradation.[42] Though in this study, the protein abundance is lower in grade 3 steatosis.
GC, LRG1, SHBG, A1BG and CP	Lower	No direct links between these plasma proteins and liver steatosis have been reported so far. As most significant proteins were reported to be, among other functions, involved in the immune response pathways, a (low-grade) pro-inflammatory state is expected in the steatosis phenotype.
Metabolites		
AAs and Biogenic amines	Depending on molecular species	Glutamate has also been reported to be positively associated with higher BMI.[21] Branched AAs (Ile, Leu, Val) on the other hand have been reported to be decreased in patients with hepatic encephalopathy in advanced chronic liver disease.[43] Furthermore, they are also associated with metabolic health[44] and with insulin resistance, having an increased concentration in blood of diabetic mice, rats, and humans.[45] As alteration of amino acid concentrations, as well as changes in biogenic amine abundances, have been attributed and found associated with numerous different metabolically unhealthy phenotypes. These are therefore disregarded as potential molecular drivers specific for hepatic steatosis in humans.
H1	Higher	The carbohydrate metabolism is affected by liver steatosis.
(Acyl)carnitines	Higher, except for C12-DC	Acylcarnitines are primarily involved in the beta oxidation of fatty acids, facilitating the transport of acetyl-CoA across mitochondrial membranes. Generally, dysregulation of acylcarnitine production indicates a dysregulated immune system or damage to the liver.[46]
Lipids		
PCs	Lower, except for PC aa C32:1	PCs are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling, such as in the early stages of the inflammatory cascade.[47]
LysoPCs	Lower	As lysoPCs have a number of anti-inflammatory effects, such as binding G protein-coupled lysophospholipid receptors. Decreased levels of lysoPCs have been observed in liver cirrhosis with increased mortality risk.[48] Decreased lysoPCs have also been associated with pre-diabetes[49], obesity[50], and type 2 diabetes[51,52], although the underlying mechanisms linking these lipids with the disease progression are poorly understood. Similar mechanisms are expected to occur in grade 3 steatosis.
SMs	Lower	SMs are major components of low-density lipoprotein (LDL) particles, and were reported to be associated with increased risk of type 2 diabetes[51,53], although the association appears to be BMI dependent.[54] The hydroxylated sphingomyelin has been cited as pre-diagnostic circulating marker, reduced with higher colorectal cancer risk and higher in breast cancer patients.[55,56]

In contrast to the proteomics and metabolomics results, no significant differences in macronutrient intake were found between control individuals and those with grade 3 liver steatosis. However, higher steatosis grades were associated with lower adherence to the Plant-based Diet Index (PDI), indicating reduced consumption of plant foods. Sensitivity analyses including the PDI score as a covariate showed similar results to the original analyses, suggesting that dietary habits did not influence the observed differences in circulating proteins, metabolites, and lipids.

These findings support the concept that the circulating biomolecular landscape of steatosis is not only influenced by hepatic pathology but is also shaped by systemic metabolic health. As such, distinguishing between different metabolically healthy and unhealthy states may provide a more mechanistically relevant framework for biomarker discovery than strictly dichotomous steatosis phenotyping alone.

Limitations of the study

Despite the strengths of our cohort design, such as fasting-state sample collection, deep phenotyping, liver health phenotyping as performed in clinical practice, and recruitment from a single demographically consistent population, several limitations must be acknowledged.

First, we relied exclusively on plasma and serum samples, limiting the resolution of tissue-specific insights. While most of the measured plasma proteins are known to originate from the liver, small molecules like lipids and metabolites have more diverse systemic sources. As such, their circulating levels may not accurately reflect liver-specific alterations. The inclusion of liver biopsies would allow deeper molecular profiling, but such invasive sampling is not appropriate in a (generally healthy) population cohort and should instead be conducted within a patient cohort.

Second, general limitations to the fields of proteomics and metabolomics are the relatively modest size of the proteomics and targeted metabolomics panels and the lack of completeness of biochemical pathways, both regarding specificity in the organism, tissue or cellular location, as well as incompleteness regarding regulatory/signaling/transport events. Interpretation of pathway analysis results presently requires extensive manual evaluation and expert know-how. This applies in particular to metabolites and lipids, which can originate either from food uptake or metabolism and biosynthesis, or even from microbial intermediate processes. Current pathway enrichment methods are more useful in the transcriptomics field than when working with the end-products of the metabolism and biochemical pathways.

Third, the untargeted metabolomics approach, while broad in scope, suffers from incomplete metabolite annotation. The absence of comprehensive MS/MS spectral libraries limited our ability to assign identities to a substantial portion of detected features. These non-annotated molecules may hold important biological relevance, particularly in steatosis progression, and should be a focus of future research.

Perspectives

This dataset opens new avenues for research beyond binary classifications of steatosis or fibrosis. Our findings suggest that many of the molecular differences identified are not necessarily unique to steatosis but instead reflect a broader metabolically unhealthy phenotype. As such, future work could reframe from the analytic approach to focus on metabolic health status rather than strict histological groupings.

Given the individual variability in disease progression, with some patients progressing slowly from steatosis to MASH or fibrosis, and others doing so rapidly, there is a clinical need for predictive biomarkers that can

identify individuals at high risk for progression. Our findings offer potential candidates, but further longitudinal studies and mechanistic validations are required.

Moreover, the non-annotated metabolites identified in our untargeted analysis represent a largely unexplored space. Targeted follow-up studies, incorporating MS/MS validation and pathway analysis, could uncover novel pathways involved in hepatic dysfunction and systemic metabolic health.

In conclusion, while this study presents valuable insights into the biomolecular signatures of hepatic steatosis, it also highlights the complexity of interpreting such data in the context of metabolic comorbidities. A shift toward understanding metabolic health as a continuum, supported by robust molecular phenotyping, may improve our capacity to identify individuals at risk and develop targeted interventions for hepatic steatosis, MASH or fibrosis and more generally MASLD.

Conclusion

Through plasma proteomics and serum metabolomics and lipidomics, we were able to identify several proteins, metabolites and lipids from different metabolic pathways associated with liver steatosis, which may provide further understanding about the pathogenesis and the progression of the disease.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The CHRIS study thank all study participants, the Healthcare System of the Autonomous Province of Bolzano Bozen - South Tyrol, and all Eurac Research staff involved in the study (https://www.eurac.edu/chrisack). Bioresource Impact Factor Code: BRIF6107.

Funding

The CHRIS study was funded by the Autonomous Province of Bolzano/Bozen - South Tyrol -Department of Innovation, Research, University and Museums and supported by the European Regional Development Fund (FESR1157).

Author Contributions

Conceptualization, MDG, JR, CG; Data curation, MDG, JR; Formal analysis, MDG, ND, EH, PL, CP, HT, MR, JR, CG; Funding acquisition, CP, FSD, PPP, HT, JR, GC; Investigation, MDG, ND, EH, PL, VVH, JR, CG; Methodology, MDG, ND, EH, PL, VVH, CP, HT, MR, JR, CG; Project administration, MDG, JR, CG; Resources, MDG, ND, EH, PL, CP, FSD, MR, PPP, HT, MR, JR, CG; Software, MDG, EH, PL, JR; Supervision, EH, FSD, CP, JR, CG; Validation, MDG, EH, CP, JR, CG; Visualization, MDG, JR; Writing – original draft, MDG, EH, PP, JR, CG; Writing – review and editing, MDG, ND, EH, PL, VVH, CP, FSD, PPP, HT; MR, JR, CG. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The Ethics Committee of the Healthcare System of the Autonomous Province of- Bolzano/Bozen - South Tyrol approved the CHRIS NAFLD protocol on 22 September 2016 (85-2016). The study conforms to the Declaration of Helsinki, and with national and institutional legal and ethical requirements.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability

Data and samples can be requested for clearly defined research activities via the CHRIS Portal (https://chrisportal.eurac.edu/). Contact the corresponding author for details. Full results of the present analyses are provided in the supplementary documents. The data analysis workflows are available at https://github.com/EuracBiomedicalResearch/nafld_proteo_metabolomics.

References

1. Lu, H., Zeng, L., Liang, B., Shu, X. & Xie, D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch. Med. Res. 40, 571–575 (2009).

2. Mencin, A. A. & Lavine, J. E. Advances in pediatric nonalcoholic fatty liver disease. Pediatr. Clin. North Am. 58, 1375–1392, x (2011).

3. Kasper, P. et al. NAFLD and cardiovascular diseases: a clinical review. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. 110, 921–937 (2021).

4. Assarrar, I. et al. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study. Rev. Diabet. Stud. RDS 18, 140–145 (2022).

5. Nemer, M., Osman, F. & Said, A. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database. Ann. Hepatol. 29, 101491 (2024).

6. D'Adamo, E. et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 33, 1817–1822 (2010).

7. Cook, J. R., Hawkins, M. A. & Pajvani, U. B. Liver insulinization as a driver of triglyceride dysmetabolism. Nat. Metab. 5, 1101–1110 (2023).

8. Castelnuovo, G. et al. A Healthful Plant-Based Diet as an Alternative Dietary Approach in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients 16, 2027 (2024).

9. Zouaoui Boudjeltia, K. et al. Effects of oxygen therapy on systemic inflammation and myeloperoxidase modified LDL in hypoxemic COPD patients. Atherosclerosis 205, 360–362 (2009).

10. Bhattachar, S. N., Deschenes, L. A. & Wesley, J. A. Solubility: it's not just for physical chemists. Drug Discov. Today 11, 1012–1018 (2006).

11. Hall, F. M. Mammographic screening in younger women at high risk. AJR Am. J. Roentgenol. 193, 1188; author reply (2009).

12. Blaudeau, T. E., Hunter, G. R. & Sirikul, B. Intra-abdominal adipose tissue deposition and parity. Int. J. Obes. 2005 30, 1119–1124 (2006).

13. Longstreth, G. F. et al. Functional bowel disorders. Gastroenterology 130, 1480–1491 (2006).

14. Molloy, J. W. et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatol. Baltim. Md 55, 429–436 (2012).

15. Malandris, K. et al. Accuracy of Controlled Attenuation Parameter for Liver Steatosis in High-Risk Patients for MASLD Using MRI-Proton Density Fat Fraction as Reference Standard. Dig. Dis. Sci. 70, 814–824 (2025).

15. Motta, B. M. et al. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J. Transl. Med. 17, 408 (2019).

16. Pattaro, C. et al. The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. J. Transl. Med. 13, 348 (2015).

17. Lundin, R. et al. Cohort Profile: the Cooperative Health Research in South Tyrol study. Int. J. Epidemiol. 54, dyaf064 (2025).

18. Ballestri, S. et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 32, 1242–1252 (2012).

19. Henry, L., Eberly, K. E., Shah, D., Kumar, A. & Younossi, Z. M. Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. Clin. Liver Dis. 27, 373–395 (2023).

20. Bhuvanesswar, K. C. et al. Prevalence of Hepatic Steatosis and Fibrosis in Asian Indian Individuals with Type 2 Diabetes. Diabetes Ther. 16, 1797–1811 (2025).

21. Verri Hernandes, V. et al. Age, Sex, Body Mass Index, Diet and Menopause Related Metabolites in a Large Homogeneous Alpine Cohort. Metabolites 12, 205 (2022).

22. Dordevic, N. et al. Extensive modulation of the circulating blood proteome by hormonal contraceptive use across two population studies. Commun. Med. 5, 131 (2025).

23. Garcia-Larsen, V. et al. Use of a common food frequency questionnaire (FFQ) to assess dietary patterns and their relation to allergy and asthma in Europe: pilot study of the GA2LEN FFQ. Eur. J. Clin. Nutr. 65, 750–756 (2011).

24. Barbieri, G. et al. Associations Between Dietary Patterns and Kidney Health Assessed in the Population-Based CHRIS Study Using Reduced Rank Regression. J. Ren. Nutr. 34, 427–437 (2024).

25. Composition of foods integrated dataset (CoFID). GOV.UK https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-cofid (2021).

26. Vukovic, V. et al. Association of dietary proteins with serum creatinine and estimated glomerular filtration rate in a general population sample: the CHRIS study. J. Nephrol. 36, 103–114 (2023).

27. Satija, A. et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J. Am. Coll. Cardiol. 70, 411–422 (2017).

28. Braisted, J. et al. RaMP-DB 2.0: a renovated knowledgebase for deriving biological and chemical insight from metabolites, proteins, and genes. Bioinforma. Oxf. Engl. 39, btac726 (2023).

29. McGlinchey, A. J. et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 4, (2022).

30. Huang, D. Q. et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Primer 11, 14 (2025).

31. Perry, A. S. et al. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep. Med. 5, (2024).

32. Laursen, T. L. et al. Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. J. Clin. Transl. Hepatol. 10, 796–802 (2022).

33. Sira, M. M., Behairy, B. E., Abd-Elaziz, A. M., Abd Elnaby, S. A. & Eltahan, E. E. Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia. Hepat. Res. Treat. 2014, 307942 (2014).

34. Gangadharan, B., Antrobus, R., Dwek, R. A. & Zitzmann, N. Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients. Clin. Chem. 53, 1792–1799 (2007).

35. Talari, N. K. et al. Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis. IScience 27, 109709 (2024).

36. Zargar, A. M., Tayebinia, H., Hasanzarrini, M., Bahiraei, M. & Mohagheghi, S. Differential levels of thyroid hormones, cortisol, and apolipoprotein M in fatty liver disease. Horm. Mol. Biol. Clin. Investig. https://doi.org/10.1515/hmbci-2024-0074 (2025)

37. Perry, A. S. et al. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep. Med. 5, 101871 (2024).

38. Tao, Y., Cianflone, K., Sniderman, A. D., Colby-Germinario, S. P. & Germinario, R. J. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim. Biophys. Acta 1344, 221–229 (1997).

39. Baldo, A. et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J. Clin. Invest. 92, 1543–1547 (1993).

40. Niu, L. et al. Dynamic human liver proteome atlas reveals functional insights into disease pathways. Mol. Syst. Biol. 18, e10947 (2022).

41. Perry, A. S. et al. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep. Med. 5, 101871 (2024).

42. Lu, Y. et al. Gelsolin's Protective Role in MASH through F-Actin Regulation and P53 Degradation. Adv. Sci. Weinh. Baden-Wurtt. Ger. 12, e2416489 (2025).

43. Marrone, G. et al. Branched chain amino acids in hepatic encephalopathy and sarcopenia in liver cirrhosis: Evidence and uncertainties. World J. Gastroenterol. 29, 2905–2915 (2023).

44. Batch, B. C. et al. Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism 62, 961–969 (2013).

45. Lynch, C. J. & Adams, S. H. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat. Rev. Endocrinol. 10, 723–736 (2014).

46. Chung, K.-P. et al. Increased Plasma Acetylcarnitine in Sepsis Is Associated With Multiple Organ Dysfunction and Mortality: A Multicenter Cohort Study. Crit. Care Med. 47, 210–218 (2019).

47. Cas, M. D., Roda, G., Li, F. & Secundo, F. Functional Lipids in Autoimmune Inflammatory Diseases. Int. J. Mol. Sci. 21, 3074 (2020).

48. Knuplez, E. & Marsche, G. An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System. Int. J. Mol. Sci. 21, 4501 (2020).

49. Wang-Sattler, R. et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol. Syst. Biol. 8, 615 (2012).

50. Heimerl, S. et al. Alterations of plasma lysophosphatidylcholine species in obesity and weight loss. PloS One 9, e111348 (2014).

51. Suvitaival, T. et al. Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men. Metabolism. 78, 1–12 (2018).

52. Razquin, C. et al. Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial. Diabetes Care 41, 2617–2624 (2018).

53. Floegel, A. et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62, 639–648 (2013).

54. Lemaitre, R. N. et al. Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study. Diabetes 67, 1663–1672 (2018).

55. Harewood, R. et al. Association between pre-diagnostic circulating lipid metabolites and colorectal cancer risk: a nested case–control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). eBioMedicine 101, 105024 (2024).

56. Qiu, Y. et al. Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer Patients. Int. J. Mol. Sci. 14, 8047–8061 (2013).